tbuckley/cabot-search huggingface dataset:
Abstract P5-03-13: The anticancer effects of Supinoxin® (RX-5902) in triple-negative breast cancer MDA-MB-231 through phosphorylated p68 on Tyr593
Authors: DJ Kim, MY Yang, YB Lee, J Remenyi, F Fuller-Pace
Journal: Cancer Research (2016)

Abstract Several studies have indicated that the DEAD box RNA helicase DDX5/p68 plays several important roles in cancer (1, 2). In particular, p68 that is phosphorylated on Tyr593 has been shown to be associated with cell transformaton, epithelial mesenchymal transition (EMT) and cell migration (3). Therefore, phosphorylated p68 may be a promising target for novel anti-cancer therapeutics. We previously reported that 1-(3,5-dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902, Supinoxin®) inhibits the growth of cancer cells at low nanomolar concentrations by interacting with phosphorylated p68 on Tyr593, interfering with the phosphorylated p68-β-catenin signaling pathway (4). In this study, we sought to determine whether phosphorylated p68 on Tyr593 plays a key role in RX-5902's ability to inhibit cancer cell growth by knocking down p68. p68-siRNA efficiently down-regulated the expression of phosphorylated p68 on Tyr593 as well as p68 in the triple-negative (TN) breast cancer cell line, MDA-MB-231. Exposure of p68-siRNA-transfected cells to the IC50 concentration of RX-5902 protected MDA-MB-231 cells from the cytotoxic effects of RX-5902, indicating the phosphorylated p68 on Tyr593 is a key molecule for RX-5902 cytotoxic effects. We also examined the tumor growth inhibition (TGI) of RX-5902 in the human TN-breast tumor (MDA-MB-231) xenograft mouse model. Not only did RX-5902 demonstrate potent efficacy in this model but also oral administration with RX-5902 resulted in dose-dependent TGI and extended the overall survival of these animals. Oral administration of 160, 320 and 600 mg/kg of RX-5902 showed 54.4%, 84.4% and 100% TGI, respectively whereas 5 mg/kg of Abraxane (iv) showed only 48.2% TGI at day 29. Further studies demonstrated the inhibitory effects of RX-5902 on cellular motility in MDA-MB-231 in wound healing assays, suggesting the potential function of phosphorylated p68 on Tyr593 in cell migration (5). These data support the potential therapeutic activity of RX-5902 in triple negative breast cancers. A Phase 1 study of RX-5902 on relapse/refractory solid tumors is ongoing. References 1. Fuller-Pace, FV, RNA Biology 10, 121–132 (2013) 2. Dai et al. Journal of Experimental &amp; Clinical Cancer Research, 33, 64-71 (2014 3. Yang et al., Cell, 127, 139–155 (2006) 4. Kost et al., Journal of Cellular Biochemistry ;online: 3 FEB 2015 05:14PM EST | DOI: 10.1002/jcb.25113) (2015). 5. Remenyi et al, presented at 2015 AACR (2015). Citation Format: Kim DJ, Yang MY, Lee YB, Remenyi J, Fuller-Pace F. The anticancer effects of Supinoxin® (RX-5902) in triple-negative breast cancer MDA-MB-231 through phosphorylated p68 on Tyr593. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-03-13.
Sympathoadrenomedullary hyperactivity in the neuroleptic malignant syndrome: a case report
Authors: J H Feibel, R B Schiffer
Journal: American Journal of Psychiatry (1981)

The authors describe a patient with the neuroleptic malignant syndrome whose excessive catecholamine excretion indicates hyperactivity of the sympathoadrenomedullary component of the autonomic nervous system. Their finding provides a physiological basis for using catecholamine blocking agents to treat some patients with this syndrome.
Abstract 134: Targeting NLMP prevents drug adaptive prostate cancer evolution
Authors: Yingqiu Xie, Haiyan Fan, Limara Manarbek, Ayan A. Nurkesh, Qing Yang, Aisulu Maipas, Zhenbang Chen
Journal: Cancer Research (2020)

Tumour necrosis factor (TNF) is synthesized initially as a membrane-bound precursor which is then cleaved to yield soluble, mature protein. The 26,000 MW TNF precursor isolated from the lysate of activated RAW 264.7 (mouse macrophage) cells by immunoprecipitation was used to identify pro-TNF cleavage enzyme in the same cells. A significant amount of mature protein was formed in samples containing Nonidet P-40 (NP-40)-lysed cells, whereas sonicated cells showed negligible activity. Most of the cleavage activity in macrophages was localized in the membrane/particulate fraction and remained largely insoluble after sonication or treatment with 2 mM EDTA/1 M NaCl, indicating that the enzyme is associated with the membrane/particulate fraction. The crude cleavage activity in membrane/particulate was partially inhibited by a spectrum of serine, cysteine and aspartate proteinase inhibitors, whereas secretion of TNF from activated macrophages was inhibited exclusively by serine and serine/cysteine proteinase inhibitors. This result suggested that, among heterogenous pro-TNF cleavage activities, the enzyme responsible for the processing of TNF is a serine proteinase. Pro-TNF cleavage activity was present in non-stimulated macrophages and decreased significantly 8 hr after lipopolysaccharide (LPS) stimulation, suggesting that it is negatively regulated after an initial burst of TNF synthesis.
Abnormal Raman Scattering by Plasma of Patients With Cancer&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: S P Verma, D F Wallach, J R Philippot, M Zanca, B Bonnet
Journal: JNCI Journal of the National Cancer Institute (1987)

Abnormal Raman Scattering by Plasma of Patients With Cancer12 JNCI: Journal of the National Cancer Institute, Volume 78, Issue 3, March 1987, Pages 587–589, https://doi.org/10.1093/jnci/78.3.587 Published: 01 March 1987
Aryl hydrocarbon receptor–dependent enrichment of a megakaryocytic precursor with a high potential to produce proplatelets
Authors: Catherine Strassel, Nathalie Brouard, Lea Mallo, Nicolas Receveur, Pierre Mangin, Anita Eckly, Ivan Bieche, Karin Tarte, Christian Gachet, François Lanza
Journal: Blood (2016)
Current Status of the Gene-Tox Program
Authors: A E Auletta, L D Kier, A D Mitchell
Journal: Environmental Health Perspectives (1991)

The U.S. Environmental Protection Agency's Gene-Tox Program is a multiphased effort to review and evaluate the existing literature in assay systems available in the field of genetic toxicology. The first phase of the Gene-Tox Program selected assay systems for evaluation, generated expert panel reviews of the data from the scientific literature, and recommended testing protocols for the systems. Phase II established and evaluated the database of chemical genetic toxicity data for its relevance to identifying human health hazards. The ongoing phase III continues reviewing and updating chemical data in selected assay systems. Currently, data exist on over 4000 chemicals in 27 assay systems; two additional assay systems will be included in phase III. The review data are published in the scientific literature and are also publicly available through the National Library of Medicine TOXNET system. The review and analysis components of Gene-Tox comprise 45 published papers, and several others are in preparation. Differences that have been observed between Gene-Tox and National Toxicology Program databases relative to the sensitivity, specificity, accuracy, and predictivity of genetic toxicity data compared to carcinogenesis data are ascribable to differences between the two databases in chemical selection criteria, testing protocols, and chemical class distributions.
A False-Negative Case of Primary Central Nervous System Lymphoma on 11C-Methionine PET and Intense 18F-FDG Uptake
Authors: J.R. García-Garzon, Diego Villasboas-Rosciolesi, Miguel Baquero, Pere Bassa, Marina Soler, Eduard Riera
Journal: Clinical Nuclear Medicine (2016)

We report a case of a 44-year-old man with neurological symptoms and MRI findings, which were unable to differentiate between glioma and lymphoma. Metabolic characterization by means of PET imaging with F-FDG and C-methionine is proposed to determine the benign or tumor (high- and low-grade) origin of brain lesions. In this case, the MRI lesion corresponded with an inconclusive metabolic pattern of intense F-FDG uptake and no significant C-methionine uptake. Pathological study revealed a false-negative case of C-methionine due to lymphoma.
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer.
Authors: C Erlichman, S Fine
Journal: Journal of Clinical Oncology (1987)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1987.5.9.1492 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3305796 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer. C ErlichmanxC ErlichmanSearch for articles by this author , S FinexS FineSearch for articles by this author https://doi.org/10.1200/JCO.1987.5.9.1492 PDF "5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer.." Journal of Clinical Oncology, 5(9), pp. 1492–1493© 1987 by American Society of Clinical Oncology
Heart Transplantation
Authors: Ward Casscells
Journal: New England Journal of Medicine (1986)

IN June 1986, Dr. Otis Bowen, secretary of the Department of Health and Human Services (DHHS), announced that Medicare will now cover heart transplantations — at specified centers — thus bringing to a close another chapter in a long, wrenching debate that has been watched closely as an augury for similarly expensive but lifesaving procedures. The proposed regulations, discussed in detail later in this essay, were issued on October 17, to become final on November 17, after the 30-day period for comment.Heart transplantation has been a kind of test case in medicine's new economic era. Clinicians and families who . . .
Case 47-1975
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, William R. McCabe, James J. Galdabini
Journal: New England Journal of Medicine (1975)

Presentation of CaseA 64-year-old man was admitted to the hospital because of a fever of unknown origin.At the age of 16 years he was found to have pulmonary tuberculosis and was admitted to a sanatorium, where he was treated with repeated left pneumothorax. He was then well until two years before admission, when urinary frequency and nocturia developed, and he was given antibiotics and prostatic massage. Fifteen months before entry he began to have a cough productive of yellow sputum, followed by fever and urinary frequency, without dysuria. He entered another hospital, where examination disclosed prostatic enlargement. The . . .
Abstract P1-09-04: New Orleans has the highest incidence rates of triple negative breast cancer
Authors: MM Loch, X Li, M-C Hsieh, VW Chen, X-C Wu
Journal: Cancer Research (2016)

Abstract Background: We previously demonstrated increased incidence rates of triple negative breast cancer (TNBC) in Black women (BW) in New Orleans (NO) and Louisiana (LA) compared with SEER 17. We explored the hypothesis that BW in NO had a higher incidence of TNBC than in BW other metro areas in the SEER Program. Methods: We analyzed tumor characteristics of invasive female breast cancers diagnosed 2010-12 from SEER, focusing on racial disparities. We compared LA data with SEER 17 and metropolitan areas (Atlanta, Detroit, Los Angeles and San Francisco). Predictors of TNBC were identified in multivariate logistic regression. Results: Overall incidence rate of TNBC in BW was significantly higher in NO (32 per 100,000) than in the rest of LA (24 per 100,000) and the SEER metro areas combined (23 per100,000). Detroit had the 2nd highest rates (27.3 per 100,000) followed by Los Angeles, San Francisco and Atlanta (23.2, 23, 22.4 respectively). Compared with SEER 17, the rate ratio of TNBC was 38% higher for BW in NO (CI: 1.17-1.61) and 17% higher for BW in Detroit (CI: 1.06-1.29). Compared with other LA metro areas, the rate ratio of TNBC was 44% higher for BW in NO (CI: 1.10-1.91). Young age (&amp;lt;65) and black race predicted TNBC after adjusting for insurance status, tumor size, lymph node status, grade and derived AJCC stage. Conclusions: The incidence rates and rate ratios of TNBC in BW in NO and LA are not only significantly higher than in SEER 17 but also higher than any other SEER metro area. We will explore this dataset further by analyzing BMI, comorbidities and SES. This disparity in BW in NO has clinical implications and translational research potential as it enables us to broaden the understanding and treatment of this aggressive disease. Citation Format: Loch MM, Li X, Hsieh M-C, Chen VW, Wu X-C. New Orleans has the highest incidence rates of triple negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-09-04.
Abstract P1-07-17: Breast cancer presentation in the over 70s
Authors: J Murray, L Smith, A Lannigan
Journal: Cancer Research (2016)

Abstract Aims: Life expectancy of the population in rising, and the risk of breast cancer increases with age. Older patients with breast cancer generally present later with more advanced disease for a variety of factors. We aimed to explore the presentation of the over 70s with breast cancer, along with their attitudes towards screening. Methods: A questionnaire was sent to patients aged over 70 at the time of their breast cancer surgery within the three hospitals across NHS Lanarkshire. This detailed reasons and timing of presentation, in addition to thoughts about screening. Results: Three hundred and fifty-two questionnaires were sent to women with a mean age of 76 years, 230 were returned (65%). Sixty-four percent routinely examined their breasts with more identifying a lump themselves (70%). Knowledge of signs and symptoms beyond a lump was explored, explicitly asking about nipple inversion, nipple discharge and skin changes with all three having similar degrees of awareness (40%, 35%, 25% respectively). Distressingly only 36% of our patients were aware of any of these signs, with only 9% being aware of all three. The majority of women sought medical attention early after identifying a problem, with 39% seeing someone within days and only 6% waiting over 6 months. Personal concern was the greatest prompt for women to see a doctor (68%) followed by family or friend concern (10%). With regard to screening, 83% routinely attended screening when they were invited. Ninety percent also said they would attend if the service was routinely offered to the over 70s. Although the majority (60%) were not aware that they could opt into the screening service once over 70. Conclusions: Despite the belief that most older women are felt to be less breast aware than younger most of our patients routinely examined themselves and identified the pathology, before promptly seeking medical advice (70% within weeks). This is the case despite most women having no knowledge of other signs and symptoms of breast cancer. Our cohort have also shown that they are keen to continue screening over the age of 70 if it was routinely offered. Citation Format: Murray J, Smith L, Lannigan A. Breast cancer presentation in the over 70s. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-07-17.
How much MOPP?
Authors: S J Horning
Journal: Journal of Clinical Oncology (1989)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1989.7.12.1766 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2585017 How much MOPP? S J HorningxS J HorningSearch for articles by this author https://doi.org/10.1200/JCO.1989.7.12.1766 First Page PDF © 1989 by American Society of Clinical Oncology
Reply to Mohammed &amp; Rembacken
Authors: Ian Gralnek
Journal: Endoscopy (2015)

We would like to thank Drs. Mohammed and Rembacken for their interest in our study [1]. In their letter to the editor, Drs. Mohammed and Rembacken suggested that “the study population was enriched and does not represent the ‘all comers’ encountered in day-to-day practice.” However, when the breakdown of specific indications for colonoscopy in our study [1] is analyzed, it is comparable to that in other published studies evaluating enhanced adenoma detection technologies, and is quite representative of what is encountered in daily practice (screening 57.5 %, surveillance 23.5 %, diagnostic colonoscopy 19 %). Therefore, we believe the polyp burden in the study cohort was no higher than what would be expected in daily practice, making the 53.2 % polyp detection rate in this study quite impressive [2] [3]. Furthermore, the authors’ claim that we included in our study only a “highly selected study group” is not completely accurate considering the pilot and feasibility design of our study evaluating new endoscopic technology, and considering that the inclusion/exclusion criteria are comparable to those in other published studies in the field [2] [3] [4] [5]. Moreover, the reported mean cecal intubation time of 4.3 minutes is also similar to that in published studies evaluating comparable technologies [2] [3]. We do agree with Drs. Mohammed and Rembacken that a limitation of our feasibility study is that it does not include a control group. However, this limitation was clearly detailed within the discussion section of the manuscript where we stated “limitations include that it is nonrandomized, with no comparison with standard forward-view colonoscopy” [1]. Moreover, we did mention that “Additional human studies should be pursued that involve comparison with standard forward-viewing colonoscopy in a back-to-back tandem design.” Indeed, intermediate results of the G-EYE tandem study [6] are intriguing, and publication of final results is awaited.
Association Between Body Mass Index and Parkinson Disease—Reply
Authors: Anne-Marie Wills, James Boyd, Adriana Pérez
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Abstract P3-12-03: Utilizing the genomically adjusted dose (GAD) to personalize radiotherapy in adjuvant breast cancer management
Authors: KA Ahmed, PS Venkat, JG Scott, RJ Diaz, WJ Fulp, JF Torres-Roca
Journal: Cancer Research (2016)

Abstract Background: We have previously validated a multi-gene model of tumor radiosensitivity (RSI) with validation in multiple independent cohorts including breast, rectal, esophageal, head and neck, glioblastoma, and prostate malignancies. Utilizing the linear quadratic model and RSI, we derived an expression for the genomically adjusted dose (GAD) to model radiation dose effect for individual patients. Methods: As RSI models the surviving fraction of cells at 2 Gy (SF2), we are able to derive a patient specific alpha. These terms were used in the linear quadratic model to calculate a GAD to model radiation effect and its association with local control. A higher GAD implies a higher predicted radiation therapy effect. Clinical and array-based gene expression were obtained from 75 ER negative patients from the Netherlands Cancer Institute (NKI) and the Institut Curie treated with breast conservation therapy. Results: Median follow-up for all patients was 10 years with a median age of 42 years (range: 23-50 years). Adjuvant radiation dose to the whole breast was 50 Gy (range: 45-55 Gy). When assessing local recurrence on multivariate analysis, we found GAD to be a significant predictor of local recurrence when dichotomized at the median (GAD-low vs GAD-high Hazard Ratio (HR) 4.5; 95% CI 1.7-13.5; p=0.0031). GAD was also significant per unit change (HR 0.91; 95% CI 0.83-0.99; p=0.021). We then modeled GAD for an escalated dose up to 60 Gy and found an additional 48% of GAD-low patients could achieve a GAD-high with dose escalation. Conclusions: We found GAD to be significantly correlated with local control following breast conservation therapy. Modeling dose escalation with GAD, we identified a select population of patients whom we hypothesize may benefit from genomically guided increased dose in the adjuvant setting. This population may represent a cohort for future clinical trial enrollment. Citation Format: Ahmed KA, Venkat PS, Scott JG, Diaz RJ, Fulp WJ, Torres-Roca JF. Utilizing the genomically adjusted dose (GAD) to personalize radiotherapy in adjuvant breast cancer management. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-12-03.
Holistic health or holistic hoax?
Authors: J. P. Callan
Journal: JAMA (1979)

Holistic health, a term increasingly bandied about with reserve or reverence depending on one's perspective, is an uncharted or at least fuzzy area for many physicians. Its proponents, a curious axis of faith healers, chiropractors, clergymen, and PhDs, along with MDs, RNs, DOs, and others without visible signs of qualifications, preach a message as old as the Bible and as American as apple pie: personal growth through self-actualization and maximum functioning of mind, body, and spirit. Their methods of achieving such laudable goals run the full gamut from laying on of hands and kinesiology through internal purging or external application of castor oil, to meditation, unusual diets, and some of the most recent scientific developments, including biofeedback. Holistic practitioners profess to treat the whole person, not simply disease. They claim traditional Western or scientific medicine is too disease oriented and splits mind from body. They not only integrate both but